^
Association details:
| Biomarker: | KIF5B-RET fusion |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
Published date:
03/14/2023
Excerpt:
...we present a case of a patient with stage IV LCNEC harboring a KIF5B–RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment.
DOI:
https://doi.org/10.3389/fonc.2023.1134151
